退市5年，龙力生物案判决出炉！1618名投资者获赔超2.7亿元

Core Viewpoint - The court ruling regarding the securities fraud liability dispute of Shandong Longli Biological Technology Co., Ltd. has been announced after five years of delisting, with 1,618 investors involved in the lawsuit claiming a total of 274 million yuan in investment loss and additional legal fees [2][5]. Summary by Sections Company Background - Longli Biological was listed on the Shenzhen Stock Exchange on July 28, 2011, under the stock code 002604, and was known as the "first stock of biofuels" [4]. - The company faced severe issues with systematic fraud, leading to its delisting from the stock exchange on July 1, 2020, after being labeled as "ST Longli" due to risk warnings [4]. Legal Proceedings - The lawsuit involved 1,628 investors who sought compensation for investment losses, commissions, and stamp duty losses from Longli Biological and associated parties, including its former chairman Cheng Shaobo and intermediary firms [5]. - The Jinan Intermediate People's Court ruled that the 1,618 plaintiffs are entitled to a total of 274 million yuan in investment loss claims and 809,000 yuan in legal fees, with additional notification fees for five representative plaintiffs [2][5]. Liability and Compensation - Cheng Shaobo is held jointly liable for the debts owed to the plaintiffs, while other defendants share liability within specified limits [2][5]. - The intermediary firm Guolian Minsheng Securities is responsible for 5% of the plaintiffs' losses, while Lixin Accounting Firm is liable for 30% [2][5]. Implications for Intermediaries - The ruling emphasizes the principle of holding primary offenders accountable while also ensuring that intermediaries are appropriately penalized based on their level of responsibility, thus maintaining a balance in liability [9].